Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicohort first-line study of TQB2868 plus anlotinib and chemotherapy in metastatic pancreatic cancer
CTR20240527Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2024
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2868 in pancreatic adenocarcinoma (PDAC), sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2024; status: active.
02
Drugs
TQB2868
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20240527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240527.